Chemical name: (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
Formula: C20H24O2

Description: AROMASIN 25mg by Pfizer is a potent medication containing the active substance Exemestane. Each tablet contains 25 mg of Exemestane, an aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. AROMASIN is renowned for its efficacy in reducing the risk of cancer recurrence and improving overall survival rates in breast cancer patients, making it a cornerstone in the management of hormone-sensitive breast cancer.

Active Substance: The active substance in AROMASIN 25mg is Exemestane, a selective irreversible aromatase inhibitor that suppresses estrogen production in postmenopausal women. By inhibiting the enzyme aromatase, Exemestane blocks the conversion of androgens into estrogen, thereby reducing estrogen levels in the body and depriving hormone receptor-positive breast cancer cells of their growth stimulus.

Indications: AROMASIN 25mg is indicated for the treatment of:

• Hormone receptor-positive breast cancer in postmenopausal women, either as adjuvant therapy following surgery or as advanced therapy for metastatic disease.
• Reduction of the risk of cancer recurrence in postmenopausal women with early-stage hormone receptor-positive breast cancer who have completed adjuvant tamoxifen therapy.

Mechanism of Action: Exemestane exerts its therapeutic effects by irreversibly binding to the active site of the aromatase enzyme, thereby inhibiting its activity and preventing the conversion of androgens into estrogen. By lowering estrogen levels, Exemestane deprives hormone receptor-positive breast cancer cells of their growth stimulus, leading to tumor regression and improved clinical outcomes.

Benefits:

• Reduced Cancer Recurrence: AROMASIN 25mg reduces the risk of cancer recurrence and improves disease-free survival rates in postmenopausal women with hormone receptor-positive breast cancer.
• Improved Survival: AROMASIN therapy has been shown to improve overall survival rates in breast cancer patients, particularly when used in the adjuvant setting following surgery.
• Well-Tolerated Profile: AROMASIN is generally well-tolerated, with manageable side effects that can be effectively managed with supportive care measures.

How to Use: AROMASIN 25mg tablets are taken orally, typically once daily, with or without food. The duration of treatment and the specific dosage regimen may vary depending on factors such as the stage of breast cancer, treatment response, and individual patient characteristics. It is essential to follow the prescribing healthcare provider’s instructions carefully and to adhere to the recommended dosage regimen.

Dosage: The recommended dosage of AROMASIN 25mg is 25 mg taken orally once daily. Treatment duration may vary depending on the specific indication and treatment response. Dosage adjustments may be necessary in patients with hepatic impairment or other comorbidities.

Efficacy: Clinical studies and real-world evidence have demonstrated the efficacy of AROMASIN 25mg in reducing the risk of cancer recurrence, improving disease-free survival rates, and enhancing overall survival in postmenopausal women with hormone receptor-positive breast cancer. Its well-established efficacy profile has solidified its position as a standard of care in breast cancer treatment.

Storage: AROMASIN 25mg tablets should be stored at room temperature, away from moisture, heat, and direct sunlight. It is essential to keep the tablets in their original packaging and to ensure that the container is tightly closed when not in use. Unused tablets should be disposed of properly according to local regulations.

Side Effects: Common side effects of AROMASIN 25mg may include hot flashes, fatigue, headache, nausea, and musculoskeletal symptoms. Less common but more serious side effects may include bone loss (osteoporosis), fractures, and cardiovascular events. Patients should be monitored regularly for adverse effects, and any concerning symptoms should be reported to the healthcare provider promptly.

Precautions: Certain precautions should be observed when using AROMASIN 25mg:

• Regular Monitoring: Patients receiving AROMASIN therapy should undergo regular medical monitoring, including bone density assessments and cardiovascular risk assessments.
• Bone Health: Patients at risk of osteoporosis or bone fractures should receive appropriate preventive measures, such as calcium and vitamin D supplementation and lifestyle modifications.
• Cardiovascular Health: Patients with pre-existing cardiovascular risk factors should be monitored closely for cardiovascular events during AROMASIN therapy.

In summary, AROMASIN 25mg by Pfizer is a valuable medication for the treatment of hormone receptor-positive breast cancer in postmenopausal women. With its potent aromatase inhibitory activity and well-established efficacy profile, AROMASIN continues to play a crucial role in improving clinical outcomes and enhancing overall survival in breast cancer patients.